ArticleBritish journal of cancer2014

The dual PI3K/mTOR inhibitor PKI-587 enhances sensitivity to cetuximab in EGFR-resistant human head and neck cancer models.

V D'Amato et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.